GlassScriptPhysician profile
Lauren Alvarez
NPI 1114579893
$6,814.82
in general payments reported to CMS, 2019-2025
34 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $1,687 · 2023: $1,675 · 2024: $1,152 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.58 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,274.95 | 2022 | |
| Ucb, INC. | $1,227.60 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $1,103.96 | 2021-2025 | Xcopri |
| Alnylam Pharmaceuticals INC. | $375.72 | 2023-2025 | Amvuttra |
| Abbvie INC. | $298.77 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $270.57 | 2023-2025 | Rexulti, Nuedexta |
| Grifols USA, LLC | $202.98 | 2022-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $183.66 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $178.26 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Greenwich Biosciences, INC. | $176.20 | 2021 | |
| Argenx US, INC. | $164.31 | 2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $151.04 | 2023-2025 | Daybue, Nuplazid |
| Eisai INC. | $147.20 | 2022-2025 | |
| Emd Serono, INC. | $141.01 | 2022-2025 | |
| Biogen, INC. | $118.42 | 2022-2025 | Vumerity, Leqembi, Tysabri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $111.12 | 2023-2025 | Valtoco |
| Xeris Pharmaceuticals, INC. | $97.15 | 2024-2025 | Keveyis |
| Merz Pharmaceuticals, LLC | $81.88 | 2023-2024 | Xeomin |
| Sumitomo Pharma America, INC. | $73.22 | 2023-2024 | Aptiom |
| Lundbeck LLC | $57.74 | 2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $49.12 | 2023-2025 | Dysport |
| Amneal Pharmaceuticals LLC | $40.08 | 2023 | Rytary |
| Catalyst Pharmaceuticals, INC. | $36.92 | 2024 | |
| Genzyme Corporation | $32.12 | 2023 | |
| Medtronic, INC. | $27.20 | 2025 | Emprint |
| Life Molecular Imaging LTD | $25.36 | 2025 | Neuraceq |
| Springworks Therapeutics, INC. | $24.58 | 2025 | Gomekli |
| Lilly USA, LLC | $22.61 | 2025 | Kisunla |
| Avion Pharmaceuticals | $22.50 | 2023 | Dhivy |
| Kyowa Kirin, INC. | $22.24 | 2024 | Nourianz |
| Pfizer INC. | $21.32 | 2025 | |
| Mdd US Operations, LLC | $21.02 | 2024 | Gocovri |
| Janssen Pharmaceuticals, INC | $18.57 | 2024 | Xarelto |
| Octapharma USA, INC. | $15.42 | 2023 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.